ACAD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
342.3M
+11.1%
308.0M
+14.9%
268.1M
-5.6%
284.0M
+1.9%
278.6M
Cost of Revenue
35.1M
+23.9%
28.3M
+14.2%
24.8M
-5.5%
26.2M
+21.1%
21.6M
Gross Profit
307.2M
+9.9%
279.6M
+15.0%
243.3M
-5.6%
257.8M
+0.3%
257.0M
Operating Expenses
235.5M
-2.6%
241.8M
-2.5%
247.9M
+3.1%
240.4M
+8.7%
221.2M
R&D
76.3M
-6.5%
81.6M
+6.1%
76.9M
-9.3%
84.8M
-3.5%
87.8M
SG&A
159.2M
-0.7%
160.3M
-6.3%
171.0M
+9.9%
155.6M
+16.7%
133.4M
Operating Income
71.7M
+89.5%
37.8M
+919.7%
-4616000
-126.5%
17.4M
-51.4%
35.8M
EBITDA
80.8M
+127.3%
35.5M
+2290.3%
-1623000
-108.0%
20.3M
-54.0%
44.1M
Net Income
53.5M
+69.9%
31.5M
+766.1%
3.6M
-98.7%
273.6M
+281.1%
71.8M
EPS (Basic)
$0.31
+72.2%
$0.18
+800.0%
$0.02
-98.8%
$1.61
+274.4%
$0.43
EPS (Diluted)
$0.31
+72.2%
$0.18
+800.0%
$0.02
-98.7%
$1.58
+276.2%
$0.42
Shares (Diluted)
175.5M
+1.5%
172.9M
+0.1%
172.7M
+0.0%
172.7M
+1.2%
170.7M
Acadia Pharmaceuticals (ACAD) — Financials